Pancreatic adenocarcinosarcoma of monoclonal origin:A case report

Adenocarcinosarcoma,a neoplasm containing both carcinomatous and sarcomatous components,is a rare form of a cancer and the pathophysiology is currently poorly understood.Moreover,definitive treatment guidelines for this disease have not yet been established.Pancreatic adenocarcinosarcoma is even mor...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 35; pp. 12682 - 12686
Main Authors Kim, Hyun Seon, Kim, Jin Il, Jeong, Minyoung, Seo, Jae Hyun, Kim, Il Kyu, Cheung, Dae Young, Kim, Tae-Jung, Kang, Chang Suk
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 21.09.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Adenocarcinosarcoma,a neoplasm containing both carcinomatous and sarcomatous components,is a rare form of a cancer and the pathophysiology is currently poorly understood.Moreover,definitive treatment guidelines for this disease have not yet been established.Pancreatic adenocarcinosarcoma is even more rare and the prognosis is fatal.Here,we report a case of a 77-year-old male with pancreatic adenocarcinosarcoma and metastasis to the liver.The patient presented at our hospital with uncontrolled glucose levels and diabetes mellitus.The patient’s laboratory findings were unremarkable with the exception of elevated carbohydrate antigen 19-9 levels.Biopsies of the tumors in the pancreas and the liver revealed two types of tumors:pancreatic adenocarcinoma and a poorly differentiated sarcoma.To determine if KRAS mutations were present,we performed a peptide nucleic acid(PNA) clamp PCR-based assay.DNA sequencing by PNA clamp PCR identified a point mutation in codon 12 of exon 2 within KRAS from both tumor types.Because the KRAS mutation is observed in both tumor components,our findings support a monoclonal tumor origin followed by subsequent divergent differentiation into the sarcomatous and carcinomatous tumor populations.After we considered the patient’s status and the late stage of tumor detection,gemcitabine chemotherapy was administered.
Bibliography:Hyun Seon Kim;Jin Il Kim;Minyoung Jeong;Jae Hyun Seo;Il Kyu Kim;Dae Young Cheung;Tae-Jung Kim;Chang Suk Kang;Department of Internal Medicine,The Catholic University of Korea,College of Medicine,Yeouido St.Mary’s Hospital;Hospital Pathology Department,The Catholic University of Korea,College of Medicine,Yeouido St.Mary’s Hospital
Author contributions: Kim HS and Kim JI designed the research; Kim HS, Kim JI, Jeong M, Seo JH, Kim TJ and Kang CS performed the research; Kim HS, Kim JI, Kim IK and Cheung DY generated reagents and analytical tools for the study; Kim HS wrote the manuscript; Kim HS and Kim JI revised the manuscript; all authors read and approved the final version of the manuscript.
Telephone: +82-2-37791519 Fax: +82-2-37791331
Correspondence to: Jin Il Kim, MD, PhD, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Yeouido St. Mary’s Hospital, 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, South Korea. jikim@catholic.ac.kr
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v20.i35.12682